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Jennifer G. Robinson, MD, MPH,* Songfeng Wang, MS,* Brian J. Smith, PHD,*
Terry A. Jacobson, MD†
Iowa City, Iowa; and Atlanta, Georgia
Objectives To determine the relationship between non–high-density lipoprotein cholesterol (HDL-C) lowering and coronary
heart disease (CHD) risk reduction for various lipid-modifying therapies.
Background Non–HDL-C is the second lipid target of therapy after low-density lipoprotein cholesterol (LDL-C).
Methods Randomized placebo or active-controlled trials were evaluated. The effect of mean non–HDL-C reduction on the
relative risk of nonfatal myocardial infarction and CHD death was estimated using Bayesian random-effects
meta-analysis models adjusted for study duration. Cochrane’s Q was used to test for heterogeneity.
Results Inclusion criteria were met by 14 statin (n  100,827), 7 fibrate (n  21,647), and 6 niacin (n  4,445) trials,
and 1 trial each of a bile acid sequestrant (n  3,806), diet (n  458), and ileal bypass surgery (n  838). For
statins, each 1% decrease in non–HDL-C resulted in an estimated 4.5-year CHD relative risk of 0.99 (95%
Bayesian confidence interval: 0.98 to 1.00). The fibrate model did not differ from the statin model (Bayes factor
K  0.49) with no evidence of heterogeneity. The niacin model was moderately different from the statin model
(K  7.43), with heterogeneity among the trials (Q  11.8, 5 df; p  0.038). The only niacin monotherapy trial
(n  3,908) had a 1:1 relationship between non–HDL-C and risk reduction. No consistent relationships were ap-
parent for the 5 small trials of niacin in combination. The 95% confidence intervals for the single trials of diet,
bile acid sequestrants, and surgery also included the 1:1 relationship.
Conclusions Non–HDL-C is an important target of therapy for CHD prevention. Most lipid-modifying drugs used as mono-
therapy have an 1:1 relationship between percent non–HDL-C lowering and CHD reduction. (J Am Coll Cardiol
2009;53:316–22) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.024l
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fihe National Cholesterol Education Program Adult
reatment Panel III (NCEP ATP III) identified non–
igh-density lipoprotein cholesterol (HDL-C) as the
econd target of therapy after low-density lipoprotein
holesterol (LDL-C) goals have been achieved in patients
ith elevated triglyceride levels between 200 and 500
g/dl (1). Non–HDL-C is calculated by subtracting
DL-C from total cholesterol, and it reflects circulating
evels of the atherogenic apolipoprotein-B– containing
rom the *Lipid Research Clinic, University of Iowa, Iowa City, Iowa; and †Emory
niversity, Atlanta, Georgia. Dr. Robinson has received research grants from Abbott,
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erck, Merck Schering-Plough, and Takeda; has received speaker honoraria from
erck Schering-Plough; and has served as a consultant for AstraZeneca and Merck
chering-Plough. Dr. Jacobson has served as a consultant for Abbott, AstraZeneca,
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esponsibility for the integrity of the data and the accuracy of the data analysis.s
Manuscript received June 16, 2008; revised manuscript received October 6, 2008,
ccepted October 7, 2008.ipoproteins including LDL-C, very low-density lipoprotein
holesterol, intermediate-density lipoprotein cholesterol,
hylomicron remnants, and Lp(a). In epidemiologic studies,
on–high-density lipoprotein is a superior predictor of
ardiovascular risk compared with LDL-C (2). The
-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
ors, or statins, the foundation for lipid-lowering therapy to
educe cardiovascular risk, also lower non–HDL-C (3). A
ecent analysis of the TNT (Treating to New Targets) and
DEAL (Incremental Decrease in End Points Through
ggressive Lipid Lowering) trials found that non–HDL-C
evels on statin therapy were a better predictor of cardiovas-
ular risk than LDL-C (4). Other nonstatin lipid-lowering
herapies, which have varying effects on LDL-C, HDL-C,
nd triglycerides, also influence non–HDL-C levels. This
nalysis will explore the relationship between non–HDL-C
eduction and CHD risk reduction, and evaluate whether
brates, niacin, bile acid sequestrants, and ileal bypass
urgery have a similar magnitude of effect as do statins.
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rticles were identified by a literature search of the MED-
INE database (1966 to May 8, 2008), English language
ournals, a manual search of the author’s reference files, and
eference lists of original articles, reviews, and meta-
nalyses. Two abstractors independently extracted informa-
ion on sample size, treatment type and duration, partici-
ant characteristics at baseline, reduction in lipids, and
utcomes using a standardized protocol and reporting form.
isagreements were resolved by consensus. Authors were
ot contacted for additional study information. For inclu-
ion in the meta-analyses, a study must have met these
riteria: 1) Studies were designed to evaluate the effect of
iet, statins, niacin, fibrates, bile acid sequestrants, or
urgery compared with an active or placebo control. 2) Studies
ad random, blinded (except for diet studies) allocation
f study participants to the treatment or control group.
) Total cholesterol and HDL-C, or non–HDL-C, were
easured at least once after baseline; measured non–
DL-C was used in the few studies in which it was
vailable, otherwise non–HDL-C was calculated from total
holesterol minus HDL-C; measured and calculated non–
DL-C were within 1 mg/dl for every study in which
on–HDL-C was measured; the interval for lipid measure-
ent was not fixed, and in some cases the values could
epresent the average during the trial. 4) For the statin trials,
rimary outcomes of the trial were clinical events; a previous
nalysis found a similar relationship between LDL-C and
HD risk reduction in statin trials with imaging as the
rimary end point compared with those trials with cardio-
ascular events as the primary end point (5); statin trials of
or more years, duration were included to provide a stable
stimate of relative risk reduction (6). 5) Study population
id not have serious noncardiovascular diseases or condi-
ions (e.g., renal or heart failure, organ transplantation).
) The CHD end points were blindly adjudicated according
o standardized criteria; coronary revascularization and un-
table angina diagnoses were excluded because of greater
emporal and regional variability in utilization and classifi-
ation (7). The analysis was confined to CHD events
ecause earlier trials did not report stroke outcomes.
tatistical methods. Because relative risks and hazard ra-
ios were not consistently reported across studies, the
tudy-specific crude relative risk and associated standard
rror was estimated from the published total number of
ubjects and incident cases in the treatment and control
roups for nonfatal myocardial infarction and CHD death.
random effects model was used for the meta-analyses.
he natural log-transformed relative risk was modeled as
linear function of the study-specific mean difference in
on–HDL-C between the 2 treatment groups and the
ean length of follow-up. For the comparative models,
reatment-non–HDL-C interaction was added to allow the
ffect of non–HDL-C lowering to vary between the 2 types
f treatments. Gaussian errors were specified as a combina- gion of the within- and between-
tudy variation. The study-
pecific standard errors for the
stimated relative risks were used
o account for within-study vari-
tion. Between-study variation
as estimated in the analysis.
ayesian methods were used to
t the random-effects meta-
nalysis models (8). A prior odds
f unity was assumed to indicate
o prior preference for the null or alternative hypothesis.
ague prior specifications were used for all regression
arameters. Additional Bayesian models evaluated the rela-
ionships between non–HDL-C and CHD risk by type of
tudy (predominant study population primary prevention,
econdary prevention [CHD or cardiovascular disease], or
iabetes mellitus) as well as between non–HDL-C and/or
DL-C and CHD risk.
Models were fit with the WinBUGS statistical soft-
are (9), and the methods of Chib (10) were used to
ompute the Bayes factor to compare the effect of
on–HDL-C between statin and nonstatin trials. A
ayes factor of 1 provides evidence that the types of
rials are similar, and a Bayes factor between 3.2 and 15
rovides moderate evidence that types of trials differ (11).
ochrane’s Q was used to test for heterogeneity with the
eta package in R 2.8 (12).
esults
or statin trials, 14 met inclusion criteria (n  100,827); all
sed statins as monotherapy, and 10 were placebo-
ontrolled (Table 1) (13–26). It should be noted that the
ROVE-IT–TIMI 22 (Pravastatin or Atorvastatin Evalu-
tion and Infection Therapy–Thrombolysis In Myocardial
nfarction 22) trial was excluded because of missing baseline
nd on-treatment total cholesterol and HDL-C levels
espite a review of multiple publications (27–29). The
EGA (Management of Elevated Cholesterol in the Pri-
ary Prevention Group of Adult Japanese) trial was also
xcluded because it was an unblinded trial comparing diet
nd diet plus pravastatin (30). For fibrate trials, 7 met
nclusion criteria (n  21,647), and all used a fibrate as
onotherapy compared with placebo: 2 used gemfibrozil
both event trials, n  6,612), 2 used fenofibrate (1 event
rial, n  10,213), and 3 used bezafibrate (1 event trial, n 
,090) (31–37). Only 2 small niacin trials met all inclusion
riteria (n  176) (38,39). Therefore, the niacin category
as expanded to include 1 large trial of niacin monotherapy
ompared with placebo that was adjudicated by an executive
ecretary (n  3,908), (40) and 4 trials using niacin in
ombination with a statin or colestipol that did not report
hether events were adjudicated (n 458) (41–44). One of
he niacin trials reported a total of 1 event in the 2 treatment
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterolroups, and the constant correction method was used
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Non–HDL-C Meta-Analysis January 27, 2009:316–2244,45). One diet (n  458) (46,47), 1 ileal bypass surgery
n  838) (48), and 1 bile acid sequestrant trial (n  3,806)
47,49) met inclusion criteria but were not included in the
nalysis comparing statins to other drugs (i.e., fibrates and
iacin). The mean duration of trials was 4.5 years.
The statin trials reported 13% to 29% decreases in total
holesterol, 0% to 13% increases in HDL-C, 10% to 22%
ecreases in triglycerides, 20% to 43% decreases in LDL-C,
nd 17% to 39% decreases in non–HDL-C between the 2
andomized, Placebo, or Active-Controlled Trials of at Least 2 Yeauration With a Primary End Point of Car iovascular Ev nts or Ath
Table 1 Randomized, Placebo, or Active-Controlled Trials of atDuration With a Primary End Point of Cardiovascular E
Study Acronym/
Trial (Ref. #) Interventions
Statins
4S (13) Simvastatin 20–40 mg Placebo
WOSCOPS (14) Pravastatin 40 mg Placebo
CARE (15) Pravastatin 40 mg Placebo
LIPID (16) Pravastatin 40 mg Placebo
AF/TexCAPS (17) Lovastatin 40 mg Placebo
HPS (18) Simvastatin 40 mg Placebo
PROSPER (19) Pravastatin 40 mg Placebo
ASCOT-LLA (20) Atorvastatin 10 mg Placebo
CARDS (21) Atorvastatin 10 mg Placebo
ASPEN (22) Atorvastatin 10 mg Placebo
A to Z Trial (23) Simvastatin 40/80 mg Simvasta
IDEAL (24) Atorvastatin 80 mg Simvasta
TNT (25) Atorvastatin 80 mg Atorvasta
SPARCL (26) Atorvastatin 80 mg Placebo
Fibrates
Helsinki (31) Gemfibrozil Placebo
VA-HIT (32) Gemfibrozil Placebo
FIELD (34) Fenofibrate Placebo
DAIS (36) Fenofibrate Placebo
LEADER (35) Bezafibrate Placebo
BIP (33) Bezafibrate Placebo
SENDCAP (37) Bezafibrate Placebo
Niacin
CDP (40) Niacin Control
FATS (38) Niacin-colestipol Conventio
CLAS II (42) Niacin-colestipol Placebo
HATS (39) Niacin-simvastatin Placebo
ARBITER 2 (43) Niacin-statin Statin
HARP (41) Pravastatin  niacin  cholestyramine 
gemfibrozil
Placebo
UCSF-SCOR (44) Colestipol  niacin 1.5 g  lovastatin Diet  co
Other
POSCH (48) Ileal bypass surgery Control
Oslo (46,47) PUFA Control
LRC (49) Cholestyramine Placeboreatment groups (Table 1). The fibrate trials reported 4% to
1% reductions in total cholesterol, 4% to 14% increases in
DL-C, 23% to 37% reductions in triglycerides, 0% to 12%
eductions in LDL-C, and 6% to 16% reductions in
on–HDL-C. The niacin trials reported 10% to 28%
eductions in total cholesterol, 13% to 38% increases in
DL-C, 18% to 52% decreases in triglycerides, 1% to 41%
ecreases in LDL-C, and 7% to 39% decreases in non–
DL-C.
lerosis Imaging
t 2 Years’
or Atherosclerosis Imaging
Duration
(yrs)
Treatment Group Control Group
N
CHD
Events N
CHD
Events
5.4 2,221 431 2,223 622
4.9 3,302 174 3,293 248
5 2,081 212 2,078 274
6.1 4,512 557 4,502 715
5.2 3,304 116 3,301 183
5 10,269 898 10,267 1,212
3.2 2,891 292 2,913 356
3.3 5,168 100 5,137 154
3.9 1,428 43 1,410 65
4 1,211 49 1,199 66
ebo/20 mg 2 2,265 234 2,232 264
40 mg 4.8 4,439 411 4,449 463
mg 4.9 4,995 434 5,006 548
4.9 2,365 81 2,366 120
5 2,046 56 2,035 84
5.1 1,264 219 1,267 275
5 4,895 256 4,900 288
3.3 207 15 211 17
4.6 783 90 785 111
6.2 1,548 211 1,542 232
3 81 2 83 4
6.2 1,119 382 2,789 1,150
erapy 2.5 48 2 52 11
4 56 18 47 22
3.2 38 1 38 12
1 87 4 80 11
2.5 44 8 47 11
l 2.2 48 0 49 1
9.7 421 82 417 125
5 229 61 229 81
7.4 1,906 155 1,900 187
Continued on next pagers’erosc
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January 27, 2009:316–22 Non–HDL-C Meta-AnalysisFor statins, a 1% decrease in non–HDL-C was associated
ith an estimated 4.5-year CHD relative risk of 0.99 (95%
ayesian confidence interval [CI]: 0.98 to 1.00)—a relative
isk decrease of 1%. Because the log-relative risk is modeled
s a linear function of non–HDL-C in the analysis, the
stimated association translates into a relative risk of 0.78
95% Bayesian CI: 0.64 to 0.94) for a 25% decrease in
on–HDL-C. The estimated relationship between de-
reases in relative risks and levels of non–HDL-C is
ontinued
Table 1 Continued
Baseline Lipids (mg/dl)
Total
Cholesterol HDL-C Triglycerides LDL-C Non–HDL-C
Total Ch
Decrea
261 46 133 188 215 25
272 44 163 192 228 20
209 39 155 139 170 20
218 36 142 150 181 18
228 38 163 156 190 19
228 41 186 150 187 20
220 50 133 147 170 13
213 51 146 132 162 24
207 59 171 117 153 27
194 47 145 114 147 18
184 39 149 111 145 25
196 46 147 121 150 21
175 47 151 98 128 14
212 50 144 133 162 29
269 47 178 189 222 10
175 32 160 112 143 4
194 43 172 119 152 11
215 39 229 131 176 10
217 43 187 130 174 8
212 35 145 148 177 5
223 39 198 142 183 7
251 41 178 — 210 10
269 38 229 175 224 17
246 44 154 171 202 25
201 31 213 125 170 26
157 40 161 89 117 0
210 41 171 135 169 28
367 51 110 275 316 22
251 40 419 179 211 23
328 29 196 260 299 23
280 44 155 205 236 13
to Z  Aggrestat to Zocor Trial; AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosis P
holesterol; ASCOT-LLA  Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Outcomes
ependent diabetes mellitus; BIP  Bezafibrate Infarction Prevention; CARDS  Collaborative Ator
HD coronary heart disease; CI confidence interval; CLAS Cholesterol Lowering Atherosclero
tudy; FIELD  Fenofibrate Intervention and Event Lowering in Diabetes; HATS  HDL-Atherosc
DEAL Incremental Decrease in End Points Through Aggressive Lipid Lowering; Incr increase; L
IPID  Long-term Intervention with Pravastatin in Ischaemic Disease; LRC  Lipid Research Clini
ravastatin in the Elderly at Risk; PUFA  polyunsaturated fatty acids; 4S  Scandinavian Simv
revention; SPARCL  Stroke Prevention by Aggressive Reduction in Cholesterol Levels; TNT  Treating t
enter of Research; VA-HIT  Veteran’s Affairs HDL Intervention Trial; WOSCOPS  West of Scotland Coummarized in Figure 1. The fibrate trials did not differ
rom statin trials (Bayes factor K  0.49). Heterogeneity
mong the fibrate trails was not detected (Q  3.66, 6 df;
 0.68).
The effect of non–HDL-C was moderately different in
he niacin trials relative to statin trials (K  7.43), with
vidence of heterogeneity among the 6 niacin trials (Q 
1.8, 5 df; p  0.038). The only niacin monotherapy
orbidity/mortality trial, which included 88% of subjects
ean % Difference Between Treatment Groups
Crude Relative
Risk Reduction
(95% CI)
HDL-C
Increase
Trig
Decrease
LDL-C
Decrease
Non–HDL-C
Decrease
8 10 35 32 31 (23 to 38)
5 12 26 25 30 (16 to 42)
5 14 28 26 23 (9 to 35)
5 11 25 23 22 (14 to 30)
5 13 27 24 37 (20 to 50)
2 19 26 25 26 (20 to 32)
5 13 34 32 17 (4 to 29)
0 17 35 31 35 (17 to 50)
0 19 40 36 35 (5 to 55)
2 14 29 25 26 (5 to 49)
13 22 41 17 13 (3 to 26)
7 21 20 19 11 (1 to 22)
0 17 24 18 21 (11 to 30)
2 16 43 39 32 (11 to 49)
10 37 10 16 34 (8 to 52)
6 31 0 6 20 (6 to 32)
4 27 12 15 11 (5 to 24)
8 28 6 14 10 (8 to 54)
8 23 8 11 19 (5 to 37)
14 25 5 9 9 (8 to 24)
8 37 10 16 49 (172 to 90)
25 27 NR 17 17 (9 to 25)
38 52 20 28 80 (16 to 95)
37 18 40 33 31 (12 to 58)
26 36 42 36 92 (39 to 99)
18 18 1 7 67 (1 to 89)
13 26 41 36 22 (75 to 66)
25 26 27 39 —
4 (20 increase) 38 28 35 (17 to 49)
4 36 27 29 25 (1 to 43)
2 (6 increase) 20 16 17 (1 to 33)
ion Study; ARBITER  Arterial Biology for the Investigation for the Treatment Effects of Reducing
SPEN  Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-insulin-
n Diabetes Study; CARE  Cholesterol and Recurrent Events Study; CDP  Coronary Drug Project;
y; DAIS Diabetes Atherosclerosis Intervention Study; FATS Familial Atherosclerosis Treatment
Treatment Study; HDL-C  high-density lipoprotein cholesterol; HPS  Heart Protection Study;
low-density lipoprotein cholesterol; LEADER Lower Extremity Arterial Disease Event Reduction;
CH  Program on the Surgical Control of the Hyperlipidemias; PROSPER  PROspective Study of
Survival Study; SENDCAP  St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular DiseaseM
ol
se
revent
Trial; A
vastati
sis Stud
lerosis
DL-C
cs; POS
astatino New Targets; UCSF-SCOR  University of California, San Francisco, Atherosclerosis Specialized
ronary Prevention Study.
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Non–HDL-C Meta-Analysis January 27, 2009:316–22ncluded in the niacin analysis (n  3,908), had a 17%
eduction in non–HDL-C and a 17% reduction in CHD
isk, in other words, a 1:1 relationship, over 6.2 years (Table
). The 95% CI of the HATS (HDL-Atherosclerosis
reatment Study) trial did not include the 1:1 line (Fig. 1).
o consistent relationships were evident for the 5 very small
rials (study size n  76 to 167) of niacin in combination
hat reported events in both treatment groups: 2 of the 3
rials that reported a non–HDL-C/CHD relative risk re-
uction relationship of 1:2 used niacin in combination
ith a statin (1:2.6 and 1:9.6), and 1 used niacin in
ombination with colestipol (1:2.9). Conversely, 1 trial of a
iacin-statin combination reported a relationship of 1:0.6.
n-treatment LDL-C levels ranged from 75 to 129 mg/dl
n those reporting a 1:1 relationship and 86 to 101 in
hose reporting a 1:1 relationship.
Because only 1 trial of each treatment met entry criteria,
rials of diet, bile acid sequestrant, and surgery were not
valuated using the Bayesian models. However, the 95% CIs
or the diet, bile acid sequestrants, and surgery trials also
ncluded a 1:1 relationship between percent non–HDL-C
owering and CHD risk (Fig. 1).
Evaluation of statin trials by type found little support for
Figure 1 Change in Relative Risk of CHD Event
Estimated change in the relative risk of a coronary heart disease (CHD) event (non
cholesterol (HDL-C) reduction with statins at a mean follow-up of 4.5 years (dashe
solid line indicates a 1:1 relationship. The crude risk estimates from the individua
are in black; fibrate trials are in red; niacin trials are in blue (UCSF-SCOR was not
3 trials, POSCH, Oslo, and LRC, were plotted but they are not included in the moddifferent relationship between non–HDL-C and CHD nisk among the trials of primary prevention (14,17,20),
econdary prevention (13,15,16,18,19,23–26), and diabetes
opulations (21,22) (K  1.48). Only 1 fibrate trial evalu-
ted a primary prevention population (31). A similar rela-
ionship between non–HDL-C and CHD occurred for
brate trials in secondary prevention (32,33,35) and diabetes
34,36,37) (K  0.41) populations. All niacin trials were
erformed in secondary prevention populations.
The Coronary Drug Project did not measure LDL-C
evels. The remaining trials were pooled to evaluate the
elationship between non–HDL-C and LDL-C and CHD
isk. The model including both non–HDL-C and LDL-C
as essentially similar to the model for non–HDL-C (K 
.01), with very minimal additional risk prediction contrib-
ted by the LDL-C change. The LDL-C changes alone
ere about one-half as accurate as the non–high-density
ipoprotein changes in predicting CHD risk reductions
LDL-C model/non–HDL-C model: K  0.43).
iscussion
long with LDL-C, non–HDL-C is an important target of
herapy for CHD prevention. The relationship between
yocardial infarction or CHD death) associated with non–high-density lipoprotein
along with the 95% Bayesian confidence interval (dashed boundary lines). The
es are plotted along with their associated 95% confidence intervals. Statin trials
d); and the POSCH, Oslo, and LRC trials are in green. The relative risks from thefatal m
d line)
l studi
plotte
eling.on–HDL-C lowering and CHD risk reduction is similar
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January 27, 2009:316–22 Non–HDL-C Meta-Analysisor statins and fibrates. Most lipid-modifying drugs used as
onotherapy appear to have an 1:1 relationship between
ercent non–HDL-C lowering and CHD reduction. Small
rial sizes and design issues limit conclusions regarding
iacin used in combination. Definitive conclusions regard-
ng greater efficacy for niacin used in combination with
tatins await the results of ongoing trials (50).
Because only 1 trial met inclusion criteria in each of the
ategories of diet, bile acid sequestrants, and surgery, the
elationship between non–HDL-C and CHD risk could
ot be evaluated in the multivariate models. However, each
reatment performed about as expected for the 1:1 relation-
hip given the percent reduction in non–HDL-C. Indeed,
hese findings are similar to those of a previous meta-
nalysis that found that diet, bile acid sequestrants, ileal
ypass surgery, and statins reduce CHD events in a 1:1
elationship with LDL-C reduction (6).
tudy limitations. Limitations of this analysis include lack
f access to patient-level data and the small numbers of
ubjects who received niacin combination therapy in
horter-term trials with unknown methods of end point
djudication. Unpublished trials were not included. We
ere not able to address the use of fibrates in combination
ith statins. Large morbidity trials of fenofibrate or niacin
sed in combination with simvastatin are ongoing (50).
onclusions
recent joint consensus report by the American Diabetes
ssociation (ADA) and the American College of Cardiol-
gy (ACC) Foundation concluded that non–HDL-C was a
etter measure than LDL-C for identifying patients at high
isk who had multiple cardiometabolic risk factors (51).
hey further concluded that non–HDL-C calculation
hould be included on all laboratory reports, and that
on–HDL-C goals should be aggressively pursued in addi-
ion to aggressive LDL-C goals. They recommended non–
DL-C goals of 100 mg/dl for all CHD patients and
iabetic patients with 1 other cardiovascular risk factor, and
goal of 130 mg/dl for all cardiometabolic risk patients
ith 2 major cardiovascular risk factors. In addition, the
ational Lipid Association has endorsed the importance of
on–HDL-C, and recommends that all laboratories begin
eporting it as an additional measure of residual cardiovas-
ular risk (52). They further concluded that non–HDL-C is
robust laboratory test, incurs no additional expense in its
alculation, and can be obtained in the nonfasting state.
lthough other lipid measures have been proposed as
ossible improvements over LDL-C measurement, non–
DL-C has as a major advantage in that it can be calculated
n all lipid profiles and measures all apolipoprotein-B–
ontaining lipoproteins that are considered atherogenic.
In summary, there is a direct, consistent relationship
etween the magnitude of non–HDL-C lowering and
ardiovascular risk reduction. These findings support the use
f non–HDL-C as an important target of therapy as
2ecommended by both the NCEP ATP III and the ADA/
CC consensus report on lipoprotein management.
eprint requests and correspondence: Dr. Jennifer G. Robinson,
ipid Research Clinic, 200 Hawkins Drive SE, 226 GH, Iowa
ity, Iowa 52242. E-mail: jennifer-g-robinson@uiowa.edu.
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